此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Antenatal High-Risk Pregnancy Intervention Bundle in Rural Nepal

2026年7月15日 更新者:University of California, San Francisco

Implementing and Evaluating an Antenatal High-Risk Pregnancy Intervention Bundle in Rural Nepal

The proposed study will assess and implement a comprehensive antenatal HRP screening and telehealth follow-up program in rural Nepal. The main questions it aims to answer are:

  1. To estimate the burden of HRPs using the existing Antenatal Risk-Score Checklist in rural Nepal
  2. Assess acceptability, feasibility, preliminary effectiveness, and implementation outcomes of the HRP bundle at the primary healthcare in Nepal

研究概览

地位

尚未招聘

条件

研究类型

介入性

注册 (估计的)

100

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Bagmati
      • Melamchi、Bagmati、尼泊尔
        • Melamchi Primary Health Care Center
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子
  • 成人
  • 年长者

接受健康志愿者

是的

描述

Inclusion Criteria:

  • all pregnant women above who are receiving antenatal care at Melamchi Primary Health Care Center

Exclusion Criteria:

  • life-threatening maternal or fetal conditions requiring immediate tertiary-level care
  • unable to provide informed consent due to cognitive or language barriers
  • do not have access to a mobile phone for telehealth consultations.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:卫生服务研究
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
无干预:Standard of Care
Usual prenatal care, including on-site consultation and visits from health facility staff
有源比较器:High Risk Pregnancy (HRP) Bundle Intervention Arm
The intervention arm would include 1. identification of high-risk pregnancy 2. Teleconsultation with expert consultant 3. weekly call with patient navigator 4. training of health care provider for HRP care, and 5. visits in the weekly prenatal telehealth clinic
The intervention would include 1. identification of high-risk pregnancy 2. Teleconsultation with expert consultant 3. weekly call with patient navigator 4. training of health care provider for HRP care, and 5. visits in the weekly prenatal telehealth clinic

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Maternal Near Miss
大体时间:up to 60 days postpartum
life-threatening complication during pregnancy, childbirth, or within 42 days postpartum, but survives with appropriate medical intervention (We will use WHO criteria)
up to 60 days postpartum

次要结果测量

结果测量
措施说明
大体时间
Neonatal death
大体时间:Up to 28 days after birth
Number of neonatal deaths, defined as death of a liveborn infant within the first 28 days of life
Up to 28 days after birth
Low Apgar Score at 5 Minutes
大体时间:At 5 minutes after birth
Number of infants with an Apgar score less than 7 at 5 minutes after birth
At 5 minutes after birth
Neonatal Intensive Care Unit Admission
大体时间:Up to 30 days after birth
Number of infants admitted to a neonatal intensive care unit
Up to 30 days after birth
Need for Mechanical Ventilation
大体时间:up to 30 days after birth
Number of infants requiring mechanical ventilation
up to 30 days after birth
Neonatal Respiratory Distress Syndrome
大体时间:Up to 30 days after birth
Number of infants diagnosed with respiratory distress syndrome
Up to 30 days after birth
Neonatal Hypoglycemia
大体时间:Up to 48 hours after birth
Number of infants with hypoglycemia, defined as less than 45 mg/dl
Up to 48 hours after birth
Low Birth Weight
大体时间:At birth
Number of infants with birth weight less than 2500 grams
At birth
Composite Adverse Neonatal Outcome
大体时间:up to 30 days after birth
Number of infants with at least one of the following: neonatal death, Apgar score less than 7 at 5 minutes, NICU admission, need for mechanical ventilation, respiratory distress syndrome, hypoglycemia
up to 30 days after birth
Antenatal Risk Screening Rate
大体时间:Up to 24 months
Proportion of pregnant women enrolled in the study who undergo antenatal risk screening using the Antenatal Risk-Score Checklist
Up to 24 months
Referral Rate
大体时间:Up to 24 months
Percentage of pregnant women referred to higher levels of care based on risks identified through antenatal risk screening
Up to 24 months
Telehealth Consultation Utilization Rate
大体时间:Up to 24 months
Proportion of pregnant women in the High Risk Pregnancy Bundle Intervention Arm who utilize at least 80% of their recommended telehealth consultations
Up to 24 months

其他结果措施

结果测量
措施说明
大体时间
Acceptability of Intervention Measure (AIM) Score
大体时间:up to 24 months
We will assess the acceptability of each intervention component (risk-screening scoring system, teleconsultation, weekly patient navigator calls, and provider training) using the mean total score and standard deviation (SD) of the Acceptability of Intervention Measure (AIM), administered at both the patient and provider level.
up to 24 months
Intervention Appropriateness Measure (IAM) Score
大体时间:Up to 24 months
We will assess the appropriateness of each intervention component (risk-screening scoring system, teleconsultation, weekly patient navigator calls, and provider training) using the mean total score and standard deviation (SD) of the Intervention Appropriateness Measure (IAM), administered at both the patient and provider level.
Up to 24 months
Feasibility of Intervention Measure (FIM) Score
大体时间:Up to 24 months
We will assess the feasibility of each intervention component (risk-screening scoring system, teleconsultation, weekly patient navigator calls, and provider training) using the mean total score and standard deviation (SD) of the Feasibility of Intervention Measure (FIM), administered at both the patient and provider level.
Up to 24 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Anju Ranjit, MD MPH、University of California, San Francisco
  • 首席研究员:Archana Shrestha、Kathmandu University School of Medicine/Dhulikhel Hospital

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年8月1日

初级完成 (估计的)

2027年7月31日

研究完成 (估计的)

2028年7月31日

研究注册日期

首次提交

2026年6月25日

首先提交符合 QC 标准的

2026年7月15日

首次发布 (实际的)

2026年7月21日

研究记录更新

最后更新发布 (实际的)

2026年7月21日

上次提交的符合 QC 标准的更新

2026年7月15日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

De-identified individual participant data will be shared, including quantitative survey data on primary outcomes (maternal near-miss) and secondary outcomes (maternal mortality, composite neonatal outcomes, stillbirth rate, preterm delivery, implementation outcomes), socio-demographic and reproductive health data, and chronic health condition data. Qualitative data (de-identified transcripts) from focus group discussions and in-depth interviews on implementation barriers and facilitators will also be shared. Process tracking data (service utilization records, monthly reports) may be shared in aggregate form. Personally identifiable information will be removed prior to sharing. Data will be shared in standard formats (e.g., Stata) in accordance with ICPSR standards, accompanied by a codebook and questionnaire to support interpretation.

IPD 共享时间框架

Individual participant data and supporting information will be available beginning at the time of publication of the associated study results. Data will remain available indefinitely upon request following publication, with no specified end date.

IPD 共享访问标准

De-identified data will be accessible to qualified researchers and program implementers who submit a formal data request and agree to comply with applicable ethical guidelines and data use terms. Requestors will have access to de-identified quantitative datasets, qualitative transcripts, and associated metadata (questionnaire, codebook). Potentially identifying variables will be classified under restricted access and made available only through a secure virtual data enclave (e.g., DSDR/ICPSR) for approved researchers. Data will be archived on a secure server at Dhulikhel Hospital-Kathmandu University Hospital, with a backup at UCSF. Requests will be reviewed by the study's Principal Investigators or designated project coordinator. A Certificate of Confidentiality will safeguard participant information throughout the access process.

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅